VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials
Williamson, C.; Curry, L.; Mkhize, N. N.; Giorgi, E. E.; Magaret, C. A.; Lambson, B. E.; Bhebhe, S.; Kaldine, H.; Moyo-Gwete, T.; Rolland, M.; Rossenkhan, R.; Garcia, N. M. G.; Moodley, C.; Yssel, A.; Huang, Y.; Marsden, A. A.; Reeves, D. B.; Mayer, B. T.; Bumgarner, R. E.; Beaume, N.; Westfall, D. H.; Juraska, M.; DeCamp, A. C.; Murrell, H. G.; Bai, H.; Deng, W.; Pankow, A.; Bhattacharya, T.; York, T.; Ndabambi, N.; Chen, L.; Zhao, H.; Gwashu-Nyangiri, A.; Thebus, R.; Cohen, P.; Murrell, B.; Karuna, S.; Hural, J.; Mgodi, N.; Edupuganti, S.; Morris, L.; Montefiori, D.; McElrath, M. J.; Cohen,
Show abstract
Broadly neutralizing antibodies (bnAbs) show promise in HIV prevention, yet viral escape remains a challenge. In the Antibody Mediated Prevention (AMP) trials, the CD4 binding site (CD4bs) bNAb VRC01 blocked acquisition by VRC01-sensitive strains. However, its influence on viral evolution post-acquisition is not fully understood. Here we analyzed >12,000 HIV env sequences from 47 participants from the AMP trials, identifying VRC01-mediated de novo escape mutations in 8 of 26 VRC01-treated participants but none in 21 placebo participants. These mutations were found at very low frequency (<1%) in global viruses. Escape mutations, primarily located in the Loop-D and {beta}23/V5 regions of Env, conferred cross-resistance to several CD4bs bnAbs, while more potent CD4bs bnAbs like N6 and 1-18 largely retained their activity. Our findings demonstrate that prophylactic VRC01 can select for viral escape after infection, underscoring the need for next-generation bnAbs with improved breadth and potency to enhance durability and efficacy of antibody-based HIV prevention.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials 97%
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 96%
- Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies 95%
Similar papers in this journal
- Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates 95%
- Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice 95%
- Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses 95%
Similar papers in this journal
Similar papers in this journal
- Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains 96%
- A rare mutation in an infant derived HIV-1 envelope glycoprotein alters interprotomer stability and susceptibility to broadly neutralizing antibodies targeting the trimer apex 95%
- The effect of single mutations in Zika virus envelope on escape from broadly neutralizing antibodies 95%
Similar papers in this journal
- HIV-1 evolutionary dynamics under non-suppressive, 2 nd -line protease-inhibitor containing antiretroviral therapy 97%
- HIV proviral burden, genetic diversity and dynamics in viremic controllers who subsequently initiated suppressive antiretroviral therapy 95%
- Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.